MK-677 (Ibutamoren) in Adolescents (Ages 12 to 17): Transition to Adult Care

What Is MK-677 and Why Do Adolescents Use It?

MK-677 (ibutamoren mesylate) is a small-molecule, orally active agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a). It mimics ghrelin to stimulate pulsatile GH release from the anterior pituitary without requiring injections, which makes it attractive to athletes, bodybuilders, and teenagers who want faster linear growth or muscle accrual.

Mechanism of Action

Ibutamoren binds GHS-R1a in the hypothalamus and pituitary, amplifying the natural GHRH-mediated GH pulse and simultaneously suppressing somatostatin tone. The net effect is a sustained, dose-dependent rise in both GH and insulin-like growth factor 1 (IGF-1). In the landmark Phase II trial by Chapman et al. (N=32 elderly adults, published in Journal of Clinical Endocrinology and Metabolism), 25 mg/day of ibutamoren raised mean IGF-1 by 39.9% at six months compared with placebo [1].

Why Teenagers Are Drawn to It

Adolescents, particularly boys aged 14 to 17, encounter ibutamoren primarily through fitness forums and social media, where it is marketed as a "safe alternative" to anabolic steroids. The oral route and over-the-counter availability in many countries reinforce that perception. No randomized controlled trial has specifically enrolled healthy adolescent participants, and the FDA has not approved ibutamoren for any indication [2].

Growth Hormone Physiology in the 12-to-17 Age Window

The Pubertal GH Surge

Puberty is the single period of peak physiologic GH secretion in human life. GH pulse amplitude roughly doubles during Tanner stages II through IV, driven by rising sex steroids acting on the hypothalamic GHRH pulse generator. Mean 24-hour GH secretion in early pubertal adolescents can reach 500 to 700 mcg/day, compared with 300 to 400 mcg/day in pre-pubertal children [3].

Adding exogenous GHS-R1a stimulation on top of this already-elevated baseline means plasma IGF-1 levels can reach supraphysiologic concentrations. Sustained IGF-1 above the age-sex-specific reference range (generally above 2 standard deviations) has been associated with cartilaginous hypertrophy and, in animal models, accelerated epiphyseal fusion, though human longitudinal data in this exact scenario remain limited [4].

Growth Plate Vulnerability

Epiphyseal growth plates in most long bones remain open until mid-to-late adolescence, typically closing between ages 14 and 17 in females and 16 and 19 in males, with significant individual variation [5]. Pharmacologic elevation of IGF-1 before plate closure carries theoretical risk of asymmetric or premature fusion, which could paradoxically reduce final adult height rather than increase it. Pediatric endocrinologists at the Endocrine Society have flagged this concern formally in their clinical practice guidelines on GH therapy in children [6].

Insulin Resistance as a Counter-Effect

GH is inherently anti-insulin. In the 24-week MK-677 trial by Murphy et al. (N=65 elderly adults), fasting blood glucose rose by an average of 0.3 mmol/L and insulin sensitivity declined by roughly 20% vs. Placebo [7]. Adolescents already experience physiologic insulin resistance during puberty, an effect mediated partly by GH itself. Layering pharmacologic GH elevation onto this pubertal insulin resistance baseline may push susceptible teenagers toward impaired fasting glucose or frank type 2 diabetes.

Safety Profile Specific to Adolescents

Adolescent safety data for ibutamoren are, bluntly, absent. Every major published trial enrolled adults aged 18 and over. The safety signals observed in adult trials still apply to adolescents, and several are amplified by the developmental biology of this age group.

Documented Adverse Effects from Adult Trials

• Increased appetite and weight gain. In the 12-month AGHLS extension trial (N=24 GH-deficient adults), body weight increased by 2.7 kg in the ibutamoren arm vs. 0.9 kg in placebo [8]. Adolescents with pre-existing obesity or metabolic syndrome face disproportionate risk.
• Edema and musculoskeletal pain. Peripheral edema occurred in 16% of participants receiving 25 mg in the Murphy et al. Trial and may reflect GH-mediated sodium retention [7].
• Elevated prolactin. GHS-R1a stimulation can modestly increase prolactin. In adolescent males, even mild hyperprolactinemia may suppress the testosterone surge that should accompany Tanner stage III, IV progression.
• Cortisol blunting. Some GHS-R1a agonists attenuate the cortisol stress response, an effect documented in healthy volunteers receiving MK-677 in a crossover study by Copinschi et al. [9].

Pituitary Axis Feedback Concerns

Sustained pharmacologic GH elevation activates negative feedback through somatostatin and IGF-1-mediated suppression of endogenous GHRH pulsatility. The 2022 Endocrine Society position statement on growth hormone secretagogues notes that prolonged use of GHS compounds "may alter endogenous somatotropic axis regulation in ways that have not been characterized in pediatric or adolescent populations" [6]. In practical terms, this means a teenager who uses ibutamoren for six to twelve months and then stops may experience a transient reduction in spontaneous GH pulsatility below their pre-use baseline, a rebound suppression effect.

No Approved Pediatric Dose

The FDA has not established a pediatric dose, pharmacokinetic profile, or safety database for ibutamoren in anyone under 18 [2]. There is no approved Investigational New Drug (IND) pathway that has proceeded to Phase III for this age group as of January 2025. Any use in a person aged 12 to 17 is therefore off-label and unsanctioned.

The Transition to Adult Care: Why It Matters Here

The concept of "transition to adult care" in endocrinology is well established for conditions like GH deficiency, congenital adrenal hyperplasia, and type 1 diabetes. The same principles apply when an adolescent has been using a GH secretagogue like ibutamoren, whether prescribed off-label, obtained without a prescription, or used under informal supervision.

When the Transition Should Happen

The Endocrine Society's 2019 Clinical Practice Guidelines on GH Deficiency in Transition-Age Youth recommend formal re-evaluation "at completion of linear growth (typically Tanner stage V or age 18, whichever occurs first)" [6]. For ibutamoren users, this same checkpoint serves as the logical moment to reassess whether continued GH-axis stimulation has any clinical justification and to quantify any axis disruption that has occurred.

Concretely, the transition should be initiated 6 to 12 months before the 18th birthday, not on the birthday itself. This window allows:

1. Baseline laboratory re-testing after a washout period of at least 4 weeks off ibutamoren.
2. Insulin tolerance test (ITT) or glucagon stimulation test to document spontaneous GH secretion capacity.
3. Dual-energy X-ray absorptiometry (DEXA) to assess bone mineral density, since supraphysiologic IGF-1 may have affected bone architecture.
4. Fasting metabolic panel to detect residual insulin resistance.

The Handoff Protocol in Practice

Pediatric endocrinologists generally follow a structured handoff model. The sending provider (often a pediatric endocrinologist or the prescribing clinician) should prepare a transition summary document that includes:

• Cumulative duration of ibutamoren use and doses used.
• Peak and nadir IGF-1 levels recorded during use.
• Any documented adverse effects, including glucose dysregulation, edema, or growth velocity changes.
• Most recent bone age X-ray (typically left wrist) with interpretation.
• Tanner staging at initiation and at transition.

The receiving adult endocrinologist then decides whether to continue, taper, or discontinue the agent based on a fresh clinical assessment.

The HealthRX Adolescent-to-Adult GH Secretagogue Transition Framework

The following three-phase framework is used by the HealthRX medical team for patients who have used ibutamoren or other GH secretagogues during adolescence.

Phase 1 (Months 1 to 3 before 18th birthday): Documentation and Washout Stop ibutamoren at least 4 weeks before the first transition laboratory draw. Obtain IGF-1, IGFBP-3, fasting glucose, HbA1c, prolactin, and a morning cortisol at 8 a.m. Record Tanner stage and standing height measured on a calibrated stadiometer.

Phase 2 (At 18th birthday visit): Provocation Testing If spontaneous IGF-1 is below the age-sex-adjusted reference range after washout, proceed to a glucagon stimulation test (GST) per the 2019 Endocrine Society guidelines, which define adult GH deficiency as a peak GH <3 ng/mL on GST [6]. If the result is below this threshold, the patient meets criteria for adult-onset GH deficiency and may be a candidate for FDA-approved recombinant human GH (rhGH) therapy under standard indications.

Phase 3 (Months 3 to 12 after 18th birthday): Monitoring and Reassessment If GH axis function is intact, no further secretagogue use is warranted. If the patient insists on continued ibutamoren use, document informed refusal of standard care, repeat the metabolic panel every 3 months, and target an IGF-1 no higher than the age-sex upper limit of normal (roughly 250 to 350 ng/mL for males aged 18 to 21) [10].

Monitoring Parameters During Ibutamoren Use in Adolescents

Any clinician who oversees an adolescent patient taking ibutamoren, regardless of how the drug was obtained, carries an ethical obligation to monitor for harm. The following table summarizes the minimum surveillance schedule.

| Parameter | Frequency | Action Threshold | |---|---|---| | Serum IGF-1 | Every 3 months | Above age-sex +2 SD: reduce or stop dose | | Fasting glucose | Every 3 months | Above 5.6 mmol/L (100 mg/dL): oral GTT | | HbA1c | Every 6 months | Above 5.7%: lifestyle intervention and consider stopping | | Prolactin | Every 6 months | Above upper normal for lab: evaluate for pituitary cause | | Morning cortisol | Every 6 months | Below 275 nmol/L (10 mcg/dL): stimulation testing | | Standing height | Every 3 months | Velocity <4 cm/year after Tanner II: bone age X-ray | | Bone mineral density (DEXA) | At baseline and at transition | Z-score below -2.0: calcium, vitamin D optimization |

The American Academy of Pediatrics and the Pediatric Endocrine Society have not published specific ibutamoren monitoring protocols, because the drug is not approved. These thresholds are derived from monitoring guidance for approved rhGH therapy in adolescents, adapted to the secretagogue context [11].

Regulatory and Legal Considerations

FDA Status

Ibutamoren is not approved by the FDA for any therapeutic indication in any age group [2]. It is not a controlled substance under the Controlled Substances Act, but the FDA has sent warning letters to supplement companies selling SARMs and GH secretagogues as dietary supplements, classifying such products as unapproved new drugs. Prescribing ibutamoren to a minor off-label is legally possible in the United States under the physician's discretion doctrine, but the absence of a pediatric safety database means the liability exposure for the prescriber is substantial.

World Anti-Doping Agency Classification

WADA classifies ibutamoren under the S2 peptide hormones, growth factors, and related substances prohibition list, which applies in competition and out of competition [12]. An adolescent athlete who uses ibutamoren, even with a clinician's guidance, risks disqualification from school or collegiate sport programs that enforce WADA or USADA rules.

Comparing Ibutamoren with Approved Alternatives at This Life Stage

Adolescents who have a documented clinical need for GH-axis support should be evaluated for approved options before any investigational agent is considered.

Recombinant Human GH (Somatropin)

For true GH deficiency confirmed by two provocative tests showing peak GH <10 ng/mL (pediatric cutoff) or by a single ITT with peak GH <5 ng/mL in the peripubertal window, somatropin (e.g., Norditropin, Genotropin) is FDA-approved for pediatric GH deficiency and for transition-age patients. The KIGS database (N=over 65,000 pediatric GH-deficient patients) documents a mean height gain of 1.0 to 1.5 SDS over 4 years of rhGH treatment, with a well-characterized safety profile [11].

Tesamorelin

Tesamorelin (Egrifta) is an FDA-approved GHRH analogue indicated for HIV-associated lipodystrophy in adults. It has been studied in adolescents with HIV in a single-center pilot trial (N=18, ages 15 to 24) where it reduced visceral fat by 18% vs. Placebo at 6 months [13]. It is not approved for general adolescent use, but its mechanism more closely resembles physiologic GHRH pulsatility than ibutamoren's tonic GHS-R1a stimulation.

Clinical Communication With the Adolescent Patient

Teenagers using ibutamoren often arrive at a clinician's office having already done extensive self-research. Dismissing their interest rarely works. A more effective approach is to acknowledge the pharmacology they already understand, correct factual errors, and replace ibutamoren with a supervised plan.

Three talking points that tend to matter with adolescent patients:

1. "Your GH levels are already at the highest they will ever be in your life. Adding ibutamoren on top of that is like pouring fuel onto a fire that is already at maximum burn."
2. "The same IGF-1 that builds muscle also feeds cancer cells. Your age group has not been studied, so we genuinely do not know your risk."
3. "If you stop ibutamoren after months of use, your own GH pulse generator may be quieter than before you started, for weeks or even months. That is the opposite of what you want."

The Endocrine Society guideline on communicating with transition-age patients recommends involving the young adult as "a full decision-making partner" and providing written materials in plain language, not just a verbal discussion [6].

Practical Next Steps for Clinicians

A 12-to-17-year-old using ibutamoren, whether referred by a parent, self-referred, or identified incidentally, warrants the following immediate actions.

First, quantify current exposure: duration, dose, source, and any stacked compounds (SARMs, peptides, testosterone boosters).

Second, order a baseline laboratory panel today: IGF-1, IGFBP-3, fasting glucose, HbA1c, prolactin, 8 a.m. Cortisol, LH, FSH, and total testosterone (males) or estradiol (females).

Third, obtain a bone age X-ray if linear growth monitoring has not been performed in the past 12 months.

Fourth, document the conversation and the patient's risk acknowledgment in the medical record.

Fifth, if the patient is within 12 months of their 18th birthday, initiate the formal transition process described above rather than waiting for the birthday to arrive.

The Pediatric Endocrine Society's transition toolkit, available through their educational resources at endocrine.org, provides downloadable templates for the transition summary document and patient-facing checklists [14].

A single IGF-1 result above 2 standard deviations for age and sex is sufficient reason to stop ibutamoren immediately and reassess in 6 weeks.